denosumab
amgen,daiichi sankyo
['denosumab']
fda approved osp meds
bisphos: (-) osteoclasts, bind to bone
denosumab: &gt; in bmd than bisphos; stopping = rebound bone loss, clusters of vert fx
anabolics for high risk osp: teripara/abalopara (pthrp)
anabolic+antiresorptive: romo
#reviewcourse
#acr22 #acrambassador 
(pronounced VUH-neet sun-dhoo) Mother. She/Her/Hers. Rheumatologist. Program Director @lluhealth. Tweets are not medical advice. #ACRAmbassador @lluhphysicians